Mallinckrodt

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focused on the development and commercialisation of therapeutics that inhibit or 'silence' the complement cascade, a group of proteins involved in the immune system that play a role in the development of inflammation.

Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target

Ligand Pharmaceuticals

Macerich

Tanger Factory Outlet Centers

Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices will decline soon.

Here Are The Stocks With The Highest Short Interest Rate

Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.

What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?

DUBLIN, Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application...

Mallinckrodt Provides Regulatory Update on StrataGraft®

Mallinckrodt (MNKKQ) closed the most recent trading day at $0.50, moving -1.76% from the previous trading session.

Mallinckrodt (MNKKQ) Stock Sinks As Market Gains: What You Should Know

DUBLIN, Jan. 29, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equality Index, the nation's foremost benchmarking survey and report measuring corporate...

Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy Court) that will extinguish all...

The Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begin Realigning Board and Management with Shareholder Interests, Renegotiate Restructuring Plan

Mallinckrodt (MNKKQ) closed the most recent trading day at $0.23, moving +1.7% from the previous trading session.

Mallinckrodt (MNKKQ) Gains As Market Dips: What You Should Know

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy Court) that will extinguish all...

The Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan

Danaos

Elevate Credit

Top Ranked Value Stocks to Buy for December 21st

U.S. Bancorp

Waterstone Financial

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th

Top Ranked Value Stocks to Buy for December 17th

News for Mallinckrodt Stock (MNKKQ)